

Joseph F Merola

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/724640/joseph-f-merola-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

172
papers

3,095
citations

30
h-index

50
g-index

218
ext. papers

4,313
ext. citations

4.4
avg, IF

5.83
L-index

#	Paper	IF	Citations
172	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.. <i>Dermatology and Therapy</i> , 2022 , 12, 495	4	6
171	Effects of Risankizumab on Nail Psoriasis in Patients with Active Psoriatic Arthritis: Results from KEEPsAKE-1.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	1
170	A novel variant in the complex locus causes Albright hereditary osteodystrophy with pseudopseudohypoparathyroidism.. <i>JAAD Case Reports</i> , 2022 , 21, 103-105	1.4	
169	Hepatitis B and C among patients with hidradenitis suppurativa: a population-based study. <i>International Journal of Dermatology</i> , 2022 , 61, 84-88	1.7	0
168	Telemedicine and psoriatic arthritis: best practices and considerations for dermatologists and rheumatologists.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	1
167	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17.. <i>Dermatology and Therapy</i> , 2022 , 12, 787	4	0
166	Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures.. <i>Scandinavian Journal of Rheumatology</i> , 2022 , 1-9	1.9	0
165	Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications.. <i>Rheumatology and Therapy</i> , 2022 , 1	4.4	0
164	Demographic and Clinical Factors Associated with Patient-Reported Remission in Psoriasis.. <i>Dermatology and Therapy</i> , 2022 , 12, 753	4	
163	Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.. <i>Dermatology and Therapy</i> , 2022 , 12, 911	4	
162	Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies.. <i>Journal of Dermatological Treatment</i> , 2022 , 1-28	2.8	
161	Topical Tofacitinib for the Management of Lymphocytic-Variant Hypereosinophilic Syndrome with Cutaneous Involvement.. <i>Dermatologic Therapy</i> , 2022 , e15518	2.2	
160	Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 321-329	4.5	13
159	Measuring fatigue: a meta-review. <i>International Journal of Dermatology</i> , 2021 , 60, 1053-1069	1.7	7
158	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2021 , 237, 151-157	4.4	4
157	Does biologic therapy impact the development of PsA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	1
156	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab076	1.1	1

155	Efficacy of Dupilumab in Atopic Dermatitis: The Patient Perspective. <i>Dermatology and Therapy</i> , 2021 , 11, 2123-2131	4	
154	Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas Psoriasis Registry. <i>Dermatology and Therapy</i> , 2021 , 12, 97	4	0
153	Does psoriasis treatment affect PsA development?. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 708-709	8.1	3
152	The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. <i>Annals of Translational Medicine</i> , 2021 , 9, 431	3.2	1
151	Clinical implications and predictive values of early PASI responses to tildrakizumab in patients with moderate-to-severe plaque psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 1-6	2.8	0
150	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. <i>JACC: Cardiovascular Imaging</i> , 2021 , 14, 2212-2220	8.4	8
149	Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2021 , 384, 1227-1239	59.2	41
148	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. <i>JAMA Dermatology</i> , 2021 , 157, 805-816	5.1	2
147	Seroconversion of severe acute respiratory syndrome coronavirus 2-infected patients on immunosuppression: A retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1409-1412	4.5	2
146	Hidradenitis suppurativa and sleep disorders: a population-based study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e520-e522	4.6	0
145	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1254-1268	4.5	42
144	Musculoskeletal Imaging for Dermatologists: Techniques in the Diagnosis and Management of Psoriatic Arthritis. <i>Dermatology and Therapy</i> , 2021 , 11, 1199-1216	4	2
143	Use of Tofacitinib, 2%, Ointment for Periorbital Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2021 , 157, 880-882	5.1	0
142	A clinical perspective on risk factors and signs of subclinical and early psoriatic arthritis among patients with psoriasis. <i>Journal of Dermatological Treatment</i> , 2021 , 1-9	2.8	1
141	Characteristics and treatment of silicone granulomas: A retrospective multicenter cohort of 21 patients. <i>JAAD International</i> , 2021 , 3, 111-114	0.9	1
140	Tofacitinib for refractory chilblain lupus erythematosus. <i>International Journal of Dermatology</i> , 2021 ,	1.7	1
139	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BELVIVID and BELREADY Phase III Trials. <i>Dermatology and Therapy</i> , 2021 , 11, 1551-1569	4	1
138	Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 495-497	4.5	3

137	De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 864-869	4.5	2
136	Axial psoriatic arthritis: An update for dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 92-101	4.5	13
135	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 300-311	4.5	7
134	Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 249-252	4.5	0
133	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021 , 60, 1137-1147	3.9	7
132	Characteristics of Patients with Psoriasis Treated with Apremilast in the Corrona Psoriasis Registry. <i>Dermatology and Therapy</i> , 2021 , 11, 253-263	4	0
131	Severe recalcitrant otic lichen planus treated with mycophenolate mofetil. <i>JAAD Case Reports</i> , 2021 , 8, 1-3	1.4	2
130	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 238-243	8.1	6
129	RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skin. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	3
128	Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021 ,	4.1	2
127	Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. <i>British Journal of Dermatology</i> , 2021 ,	4	3
126	Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 71-78	4.5	10
125	The catch-22 of limited Food and Drug Administration approval for connective tissue disease therapies. <i>Journal of the American Academy of Dermatology</i> , 2021 , 85, 517-519	4.5	0
124	Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021 , 27, 1106-1117	7.9	1
123	Decreased quality of life in people with psoriasis and psoriatic arthritis vs. people with psoriasis alone: data from a national US survey. <i>British Journal of Dermatology</i> , 2021 ,	4	0
122	Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. <i>Current Atherosclerosis Reports</i> , 2021 , 23, 67	6	5
121	Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States. <i>Journal of the American Academy of Dermatology</i> , 2021 ,	4.5	1
120	Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccination. <i>JAAD Case Reports</i> , 2021 , 17, 126-129	1.4	1

119	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. <i>Dermatology</i> , 2021 , 1-8	4.4	1
118	A case of paradoxical fibrosis and development of morphea in a patient on dupilumab. <i>JAAD Case Reports</i> , 2021 , 17, 7-8	1.4	1
117	Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 ,	4.6	0
116	Coronary microvascular dysfunction in patients with psoriasis. <i>Journal of Nuclear Cardiology</i> , 2020 , 1	2.1	7
115	Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1367-1374	4.5	28
114	Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study. <i>Patient Preference and Adherence</i> , 2020 , 14, 949-961	2.4	3
113	Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus. <i>JAMA Dermatology</i> , 2020 , 156, 901-906	5.1	6
112	Older adults on systemic treatment for psoriasis and risk of infection: a propensity score-matched population-based study. <i>British Journal of Dermatology</i> , 2020 , 183, 564-566	4	4
111	Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 1337-1345	4.5	3
110	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1150-1159	4.5	13
109	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2020 , 395, 427-440	4.0	65
108	The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis Registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2051-2058	4.6	3
107	Indoor tanning use is associated with psoriasis in the NursesQHealth Study II. <i>British Journal of Dermatology</i> , 2020 , 183, 384-386	4	
106	Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2020 , 16, 267-283	5.1	2
105	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 323-338	7.1	0
104	Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. <i>JAMA Dermatology</i> , 2020 , 156, 342-345	5.1	10
103	Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 1257-1262	4.6	6
102	Mycophenolate Mofetil for Eosinophilic Fasciitis: A Retrospective Analysis From 3 Tertiary Care Centers. <i>JAMA Dermatology</i> , 2020 , 156, 595-597	5.1	3

101	Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. <i>Dermatology and Therapy</i> , 2020 , 10, 351-364	4	13
100	Comorbidities associated with psoriatic arthritis: Review and update. <i>Clinical Immunology</i> , 2020 , 214, 108397	9	32
99	Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2809-2820	4.6	5
98	Report from the International Dermatology Outcome Measures Initiative. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2020 , 20, S80-S83	1.1	1
97	Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey. <i>Rheumatology and Therapy</i> , 2020 , 7, 617-637	4.4	8
96	Aiming for Cure and Preventive Initiatives in Psoriatic Disease: Building Synergy at NPF, GRAPPA, and PPACMAN. <i>Current Rheumatology Reports</i> , 2020 , 22, 78	4.9	6
95	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1704-1716	4.5	31
94	Psoriatic arthritis for dermatologists. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 662-679	2.8	20
93	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. <i>British Journal of Dermatology</i> , 2020 , 182, 410-417	4	16
92	Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 54-61	4.5	2
91	Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 109-117	7.1	3
90	Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study. <i>Journal of Rheumatology</i> , 2020 , 47, 548-552	4.1	12
89	Achieving Consensus on Patient-Reported Outcome Measures in Clinical Practice for Inflammatory Skin Disorders: On Behalf of International Dermatology Outcome Measures and the American Academy of Dermatology. <i>Journal of the American Academy of Dermatology</i> , 2019 ,	4.5	6
88	Plasma levels of tumour necrosis factor- α and adiponectin can differentiate patients with psoriatic arthritis from those with psoriasis. <i>British Journal of Dermatology</i> , 2019 , 181, 379-380	4	5
87	Exploration of the Product of the 5-Point Investigator-Global Assessment and Body Surface Area (IGA \times BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis. <i>Dermatology</i> , 2019 , 235, 348-354	4.4	4
86	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1215-1219	2.4	21
85	A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 102-110	4.5	28
84	A provider global assessment quality measure for clinical practice for inflammatory skin disorders. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 823-828	4.5	3

83	Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 153-166	8.1	111
82	Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity. <i>Journal of Dermatological Treatment</i> , 2019 , 30, 141-149	2.8	16
81	Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2019 , 129, 1359-1371	15.9	110
80	AB0738 DUAL NEUTRALISATION OF INTERLEUKIN (IL) 17A AND IL 17F WITH BIMEKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 60-WEEK RESULTS FROM A RANDOMISED, DOUBLE-BLINDED, PHASE 2B EXTENSION STUDY 2019 ,		1
79	OP0108 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÏVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY 2019 ,		4
78	An Approach to Retiform Purpura for the Inpatient Dermatologist. <i>Current Dermatology Reports</i> , 2019 , 8, 245-257	1.5	
77	TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019 , 4, 70-80	1.1	33
76	Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey. <i>Rheumatology and Therapy</i> , 2019 , 6, 33-45	4.4	12
75	Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value. <i>Journal of Rheumatology</i> , 2019 , 46, 160-165	4.1	12
74	Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 270-276	4.3	12
73	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 5-32	9.5	178
72	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019 , 71, 2-29	4.7	137
71	Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. <i>Dermatologic Therapy</i> , 2018 , 31, e12589	2.2	47
70	Interleukin 17, inflammation, and cardiovascular risk in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 345-352	4.5	53
69	A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process. <i>British Journal of Dermatology</i> , 2018 , 179, 642-650	4	62
68	Inflammatory arthritis and crystal arthropathy: Current concepts of skin and systemic manifestations. <i>Clinics in Dermatology</i> , 2018 , 36, 533-550	3	2
67	Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 277-286.e10	4.5	105
66	Polyarthralgias and Papulonodules in a 56-Year-Old Woman. <i>Arthritis Care and Research</i> , 2018 , 70, 925-930		17

65	Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 383-394	4.5	41
64	Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity. <i>Journal of Medical Economics</i> , 2018 , 21, 745-754	2.4	8
63	Psoriatic arthritis and the dermatologist: An approach to screening and clinical evaluation. <i>Clinics in Dermatology</i> , 2018 , 36, 551-560	3	6
62	Evaluation of sPGA/BSA as an Outcome Measure and Treatment Target for Clinical Practice. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 1955-1961	4.3	15
61	Lack of response to intravenous sodium thiosulfate in three cases of extensive connective tissue disease-associated calcinosis cutis. <i>British Journal of Dermatology</i> , 2018 , 178, 1412-1415	4	13
60	Towards global consensus on core outcomes for hidradenitis suppurativa research: an update from the HISTORIC consensus meetings I and II. <i>British Journal of Dermatology</i> , 2018 , 178, 715-721	4	20
59	Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study. <i>Rheumatology and Therapy</i> , 2018 , 5, 423-436	4.4	8
58	Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. <i>British Journal of Dermatology</i> , 2018 , 179, 844-852	4	59
57	Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. <i>Clinical Rheumatology</i> , 2018 , 37, 2751-2761	3.9	21
56	Distinguishing rheumatoid arthritis from psoriatic arthritis. <i>RMD Open</i> , 2018 , 4, e000656	5.9	50
55	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. <i>Dermatology</i> , 2018 , 234, 157-165	4.4	7
54	Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials. <i>JAMA Dermatology</i> , 2018 , 154, 1137-1144	4.4	24
53	Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. <i>JAMA Dermatology</i> , 2018 , 154, 934-950	5.1	70
52	Targeted therapies for psoriatic arthritis: an update for the dermatologist. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018 , 37, 173-181	1.4	2
51	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 345-355	9.5	51
50	Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. <i>Current Rheumatology Reports</i> , 2018 , 20, 76	4.9	15
49	Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM). <i>Dermatology</i> , 2018 , 234, 112-119	4.4	1
48	Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. <i>Archives of Dermatological Research</i> , 2018 , 310, 701-710	3.3	8

47	Protocol for the development of a core domain set for hidradenitis suppurativa trial outcomes. <i>BMJ Open</i> , 2017 , 7, e014733	3	24
46	Switching biologics in the treatment of psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 29-37	5.3	52
45	Classifying discoid lupus erythematosus: background, gaps, and difficulties. <i>International Journal of Womens Dermatology</i> , 2017 , 3, S62-S66	2	7
44	Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics. <i>Journal of Rheumatology</i> , 2017 , 44, 693-694	4.1	22
43	Polyphenotypic Psoriasis: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 695-696	4.1	0
42	Practical Assessment of Psoriasis Clinical Severity in both Clinical Trials and Clinical Practice Settings: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 691-692	4.1	1
41	Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 701-702	4.1	5
40	Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017 , 44, 674-678	4.1	15
39	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 290-298	4.5	90
38	Intralesional Sodium Thiosulfate Treatment for Calcinosis Cutis in the Setting of Lupus Panniculitis. <i>JAMA Dermatology</i> , 2017 , 153, 944-945	5.1	15
37	Development of classification criteria for discoid lupus erythematosus: Results of a Delphi exercise. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 261-267	4.5	34
36	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 23, 1177-1183	4.6	42
35	Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 79-87.e1	4.5	47
34	Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017 , 377, 1537-1550	59.2	297
33	Rationale and Design of the Brigham Cohort for psoriasis and psoriatic arthritis registry (COPPAR). <i>BMC Dermatology</i> , 2017 , 17, 11	2.1	6
32	Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA/BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data. <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 1178-1180	4.5	13
31	Novel posterior auricular cutaneous reaction after anti-TNF- α infusion in young women with Crohn's disease. <i>JAAD Case Reports</i> , 2017 , 3, 512-514	1.4	0
30	OP0216 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, or adalimumab in patients with active psoriatic arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (CSDMARDs): a randomised, placebo-controlled, phase 3 trial 2017.		3

29	SAT0222 BIIB059, a monoclonal antibody targeting BDCA2, shows evidence of biological activity and early clinical proof of concept in subjects with active cutaneous le	2017,	4
28	The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and Update. <i>Journal of Drugs in Dermatology</i> , 2017, 16, 119-124	2.2	10
27	International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group. <i>Journal of Drugs in Dermatology</i> , 2017, 16, 770-777	2.2	5
26	Histopathology of the Inner Ear in a Case With Recent Onset of Cogan Syndrome: Evidence for Vasculitis. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2016, 125, 20-4	2.1	17
25	FRI0580 Comorbidity Burden and Medication Use between Psoriatic Arthritis Patients with Moderate-To-Severe Psoriasis vs. Those with Minimal Skin Psoriasis in The US. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 651.3-652	2.4	1
24	Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 961-4	4.1	5
23	Adaptive Clinical Trial Design: An Overview and Potential Applications in Dermatology. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1325-1329	4.3	4
22	Dapsone Therapy for Pustular Psoriasis: Case Series and Review of the Literature. <i>Dermatology</i> , 2016, 232, 97-101	4.4	17
21	Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 147-62	7.1	14
20	Classifying discoid lupus erythematosus: background, gaps, and difficulties. <i>International Journal of Womens Dermatology</i> , 2016, 2, 8-12	2	5
19	Epidemiology and Treatment of Eosinophilic Fasciitis: An Analysis of 63 Patients From 3 Tertiary Care Centers. <i>JAMA Dermatology</i> , 2016, 152, 97-9	5.1	36
18	Developing classification criteria for discoid lupus erythematosus: an update from the World Congress of Dermatology 2015 meeting. <i>International Journal of Womens Dermatology</i> , 2016, 2, 44-45	2	4
17	Tofacitinib Citrate for Refractory Cutaneous Dermatomyositis: An Alternative Treatment. <i>JAMA Dermatology</i> , 2016, 152, 944-5	5.1	77
16	International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update. <i>Journal of Rheumatology</i> , 2016, 43, 959-60	4.1	7
15	Shedding Light on the "Hidden Psoriasis": A Pilot Study of the Inverse Psoriasis Burden of Disease (IPBOD) Questionnaire. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 1011-6	2.2	9
14	Psoriatic arthritis: it's as easy as "PSA". <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 905-64	4.5	10
13	Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing. <i>Journal of Rheumatology</i> , 2015, 42, 847-52	4.1	16
12	Epidemiology of concomitant psoriasis and hidradenitis suppurativa (HS): experience of a tertiary medical center. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 701-2	4.5	21

11	Psoriasis, psoriatic arthritis and risk of gout in US men and women. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1495-500	2.4	51
10	Mosaic focal dermal hypoplasia caused by a novel somatic mutation in PORCN detected in affected skin. <i>British Journal of Dermatology</i> , 2015 , 173, 568-70	4	9
9	Treatment of coexistent psoriasis and lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 253-60	4.5	29
8	The International Dermatology Outcome Measures Group: formation of patient-centered outcome measures in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2015 , 72, 345-8	4.5	31
7	Diagnosing and treating psoriatic arthritis: an update. <i>British Journal of Dermatology</i> , 2014 , 170, 772-86	4	23
6	Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. <i>Lupus</i> , 2014 , 23, 778-84	2.6	36
5	The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): a novel index to measure all non-plaque psoriasis subsets. <i>Journal of Rheumatology</i> , 2014 , 41, 1230-2	4.1	11
4	The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting. <i>Journal of Rheumatology</i> , 2014 , 41, 1227-9	4.1	16
3	Psoriatic arthritis screening tools: study design and methodological challenges. <i>British Journal of Dermatology</i> , 2014 , 170, 994-5	4	2
2	Association of discoid lupus erythematosus with other clinical manifestations among patients with systemic lupus erythematosus. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 19-24	4.5	20
1	Is chronic cutaneous discoid lupus protective against severe renal disease in patients with systemic lupus erythematosus?. <i>Journal of Drugs in Dermatology</i> , 2011 , 10, 1413-20	2.2	13